<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388035</url>
  </required_header>
  <id_info>
    <org_study_id>HHAEREDS-2015</org_study_id>
    <nct_id>NCT02388035</nct_id>
  </id_info>
  <brief_title>Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis</brief_title>
  <official_title>Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Ahmed Ali Elbaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nasser Institute For Research and Treatment</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients, and
      the changes in the microbiological characteristics reported in the last years are impacting
      the choice of antibiotic used in the treatment. Cefotaxime has been the most extensively
      studied antibiotic for this infection. It is considered to be one of the first choice
      antibiotics because of low toxicity and excellent efficacy. Treatment of SBP by intravenous
      cefotaxime should be administered for a minimum 5 days. Antibiotic-resistant microorganisms
      have been increasingly reported especially to cefotaxime and its effect on the clinical
      outcome in treating SBP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Organisms detected with their antibiotics sensitivity</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">254</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>SBP-group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spontanous bacterial peritonitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNNA-group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Culture negative neutrocytic ascites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MNBA-group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>monomicrobial non-neutrocytic ascites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no evidence of ascitic fluid infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefotaxime</intervention_name>
    <arm_group_label>SBP-group 1</arm_group_label>
    <arm_group_label>CNNA-group 2</arm_group_label>
    <arm_group_label>MNBA-group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with liver cirrhosis and ascites and clinical findings suspicious of ascitic
             fluid infection

        Exclusion Criteria:

          -  Patients were excluded if they received antibiotics ten days prior to the hospital
             admission or there is evidence of secondary bacterial peritonitis, tuberculous
             peritonitis, malignant ascites or ascites due to other causes e.g. cardiac or renal
             diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nasser institute</name>
      <address>
        <city>Cairo</city>
        <state>Shubra</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nasser Institute For Research and Treatment</investigator_affiliation>
    <investigator_full_name>Dr Ahmed Ali Elbaz</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>profiles changes</keyword>
  <keyword>microorganisms</keyword>
  <keyword>cefotaxime</keyword>
  <keyword>SBP</keyword>
  <keyword>Egyptian</keyword>
  <keyword>effective antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

